Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Hematologic Cancer Clinical Trials

A listing of Hematologic Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (38) clinical trials

The purpose of this study is to see if GS-9073 can benefit people with CLL. This study will also investigate the safety of GS-9973 and how weel the drug is tolerated.

Phase

A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders.

The open-label, multicenter, multinational rollover study is intended to evaluate the safety of CC-486, while providing continued treatment with CC-486 for subjects who are receiving single agent CC-486 at the time of transition to the rollover study and tolerated the protocol prescribed regimen in Celgene-sponsored trials, and whom in the ...

Phase

PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)

Study Treatments: Epsilon aminocaproic acid (EACA) vs. standard prophylactic platelet transfusions. Study Title: Randomized Trial of Epsilon Aminocaproic Acid versus Platelet Transfusions for the Prevention of Bleeding in Thrombocytopenic Patients with Hematological Malignancies. (PROBLEMA trial: PRevention Of BLeeding in hEmatological Malignancies with Antifibrinolytic agents (epsilon aminocaproic acid). Phase: Randomized Phase ...

Phase

BGJ398 for Patients With Tumors With FGFR Genetic Alterations

The purpose of this signal seeking study is to determine whether treatment with BGJ398 demonstrates sufficient efficacy in select FGFR pathway-regulated solid tumors and/or hematologic malignancies to warrant further study.

Phase

Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow

Patients with malignant and non-malignant hematologic diseases including severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), myelodysplastic syndrome (MDS), acute and chronic leukemias, Hodgkin's and non-Hodgkin's lymphoma and multiple myeloma (MM) can now be cured by allogeneic bone marrow transplantation (BMT). This curative effect has been ascribed to the use ...

Phase

Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK MET or ROS1

Twenty cohorts are identified, a cohort being defined as [one pathology, one target alteration] such as [gastric cancer with MET amplification (6%)]. One cohort will be dedicated to miscellaneous, very rare pediatric diseases identified through INCa platforms or pan-genome programs (e.g. MOSKIDO, IGR) and will recruit up to 10 patients. ...

Phase

Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation

This is a non-randomized, phase II protocol to evaluate engraftment of cord blood after treatment with myeloablative conditioning of fludarabine, total body irradiation and cyclophosphamide. All patients will receive tacrolimus and mycophenolate mofetil as prophylaxis for graft-vs-host disease. Conditioning Regimen: - Days -10 to -7: Fludarabine 30mg/m2/day IV - Days ...

Phase

Cyclophosphamide Fludarabine Total-Body Irradiation and Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer or Other Disease

OBJECTIVES: Primary - Determine, preliminarily, the efficacy of double-unit umbilical cord blood (UCB) transplantation (UCBT) in patients with hematologic malignancy. Secondary - Determine the incidence and rate of donor-derived neutrophil and platelet recovery in these patients. - Determine the contribution of each unit of UCB to initial and sustained engraftment ...

Phase

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

OBJECTIVES: - Determine the overall survival rate at day 200 in patients with hematologic cancers or other diseases who undergo allogeneic peripheral blood stem cell transplantation using the CliniMACS® CD34 Reagent System for T-cell depletion followed by delayed T-cell add-back. - Determine the safety of this regimen, in terms of ...

Phase

Umbilical Cord Blood Transplant Cyclophosphamide Fludarabine Phosphate and Total-Body Irradiation in Treating Patients With Hematologic Disease

PRIMARY OBJECTIVES: I. To determine the one year survival of patients undergoing umbilical cord blood transplantation (UCBT) after a myeloablative preparative regimen consisting of cyclophosphamide (CY), fludarabine phosphate (fludarabine [FLU]), and fractionated total body irradiation (TBI). SECONDARY OBJECTIVES: I. Incidence of transplant-related mortality (TRM) at 6 months. II. Chimerism at ...

Phase